NEW YORK, May 21 (Reuters) - Bristol-Myers Squibb Co.'s schizophrenia drug Abilify proved effective as an add-on therapy for patients suffering from major depression who were not getting satisfactory ...
PRINCETON, NJ and TOKYO, JAPAN, November 20, 2007 – Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) ...
TOKYO, JAPAN and PRINCETON, NJ, Nov. 6, 2007 -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results